{
  "docId": "019de073-dc46-770c-87a2-2b21d91043e5",
  "docSlug": "4f9fcbb83e828aea5419518c9cca9ae9",
  "documentTitle": "Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides",
  "authorId": "tonix-pharmaceuticals",
  "authorName": "Tonix Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 29,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "other",
  "function": "frame_situation",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a two-column layout to contrast the disease profile with the development program status.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-dc46-770c-87a2-2b21d91043e5/17",
  "deckHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5",
  "deckJsonHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5.json",
  "deckAnchorHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.42,
        "x": 0.05,
        "y": 0.69
      },
      "kind": "callout",
      "text": "Differentiator: No approved therapeutic currently on the market for hyperphagia in PWS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a997f8ac-3e08-44d2-97ab-51b8f78bb352",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.05,
        "y": 0.24
      },
      "kind": "list",
      "text": "Prader-Willi Syndrome is the most common genetic cause of life-threatening childhood obesity. Rare disease occurring in 1 in 10,000 to 1 in 30,000 births. Symptoms include lack of suckling as infants, poor muscle strength, and constant hunger (hyperphagia).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0eb84b1d-acac-4025-a0b3-d89380cb3dae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.51,
        "y": 0.24
      },
      "kind": "list",
      "text": "Market Entry: Hyperphagia in Prader-Willi Syndrome. Additional Indications: Rare Hyperphagia Conditions. Status: Preclinical, granted orphan drug designation by FDA. Next Steps: pre-IND meeting to seek agreement on development plans.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63f20c9f-7e65-4b51-976a-5e22f81f231f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.51,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "DEVELOPMENT PROGRAM",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9785f8ce-d1d1-4a34-8396-ae0189967ecf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.15,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "PROFILE",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e72febf-591b-4af0-908e-e4a42466b18d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.57,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "*TNX-2900 is in the pre-IND stage of development and has not been approved for any indication.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "130b54f3-2af2-45ea-b1e4-a934bf5ff47c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "TNX-2900*: Hyperphagia in Prader-Willi Syndrome Intranasal Potentiated Oxytocin (OT) with Magnesium",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8532d698-dcc5-431e-ba50-e3b79197f9ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "7847462f-eec4-4a6d-b385-4563a211e8af",
      "evidence": "list/bullet: Prader-Willi Syndrome is the most common genetic cause of life-threatening childhood obesity.",
      "confidence": 0.7
    },
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6858373d-e66f-439b-857f-3eedcaa48154",
      "evidence": "callout/primary: Differentiator: No approved therapeutic currently on the market for hyperphagia in PWS",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 16,
      "beatId": "61540f51-24ff-44c6-af8d-84164a6e08dc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The presentation highlights the market potential of the company's product candidates",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e532f435-d20e-4323-8595-44dab22c3ce1",
      "evidence": "The presentation uses a golden circle structure to communicate the company's mission and vision",
      "position": 0,
      "objective": "Why Tonix Pharmaceuticals?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}